Haemonetics Co. (NYSE:HAE) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC trimmed its position in Haemonetics Co. (NYSE:HAE) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,727 shares of the medical instruments supplier’s stock after selling 604 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.09% of Haemonetics worth $3,756,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP acquired a new stake in Haemonetics during the second quarter worth about $39,000. Covestor Ltd grew its holdings in shares of Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 438 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $82,000. Canada Pension Plan Investment Board bought a new stake in shares of Haemonetics in the 2nd quarter worth approximately $83,000. Finally, EntryPoint Capital LLC acquired a new position in Haemonetics during the 1st quarter valued at approximately $86,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HAE shares. Citigroup lowered their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. Bank of America initiated coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price for the company. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. BTIG Research assumed coverage on Haemonetics in a report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective for the company. Finally, Barrington Research reaffirmed an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research note on Monday, September 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $106.14.

Haemonetics Stock Up 0.4 %

HAE opened at $71.47 on Friday. The stock’s fifty day moving average is $75.46 and its 200-day moving average is $82.77. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97. The company has a market capitalization of $3.66 billion, a PE ratio of 32.05, a P/E/G ratio of 1.13 and a beta of 0.30. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same quarter last year, the firm posted $1.05 earnings per share. Haemonetics’s revenue was up 8.0% compared to the same quarter last year. On average, equities analysts predict that Haemonetics Co. will post 4.57 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.